Parallax Volatility Advisers
PCRX icon

Parallax Volatility Advisers’s Pacira BioSciences PCRX Stock Holding History

Parallax Volatility Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,357
Closed -$101K – 2003
2024
Q4 		$101K Sell
5,357
-11,521
-68% -$202K ﹤0.01% 1741
2024
Q3 		$254K Buy
+16,878
New +$289K ﹤0.01% 1656
2019
Q2 		– Sell
-132
Closed -$5K – 3385
2019
Q1 		$5K Sell
132
-9,316
-99% -$364K ﹤0.01% 2581
2018
Q4 		$406K Buy
9,448
+4,657
+97% +$217K ﹤0.01% 1561
2018
Q3 		$235K Buy
4,791
+4,757
+13,991% +$206K ﹤0.01% 1587
2018
Q2 		$1K Hold
34
– – ﹤0.01% 1995
2018
Q1 		$1K Sell
34
-5,930
-99% -$211K ﹤0.01% 2096
2017
Q4 		$272K Buy
+5,964
New +$236K ﹤0.01% 2026

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Parallax Volatility Advisers's PCRX Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 5,357 shares — an estimated $101K sold.

Parallax Volatility Advisers first reported a position in PCRX in Q4 2017 and held it in 8 quarters. The position peaked at $406K in Q4 2018. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Parallax Volatility Advisers reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,357 Pacira BioSciences shares in Q1 2025, an estimated $101K.
  • Parallax Volatility Advisers first reported a position in Pacira BioSciences in Q4 2017 and held it in 8 quarters.
  • Parallax Volatility Advisers's Pacira BioSciences position peaked at $406K in Q4 2018.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.